Bromocriptine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Bromocriptine
- Pharmacist Assessment Report
- Bromocriptine: dopamine D2 agonist → congenital disorder of glycosylation with defective fucosylation
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Bromocriptine: dopamine D2 agonist → congenital disorder of glycosylation with defective fucosylation
One-Sentence Summary
Bromocriptine is an oral dopamine D2 receptor agonist marketed in Australia as a single-ingredient tablet. The TxGNN model predicts it may be relevant to congenital disorder of glycosylation with defective fucosylation, with a score of 0.9983. No clinical trials or publications were found for this disease, so the prediction rests on the model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | congenital disorder of glycosylation with defective fucosylation |
| TxGNN Prediction Score | 0.9983 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. Bromocriptine is generally known as a dopamine D2 receptor agonist, but the data supplied do not establish any mechanism that would link this action to congenital disorder of glycosylation with defective fucosylation.
No mechanistic link was identified. The high score is a model-based prediction only. It is not supported by any trial, publication or biological rationale in the data compiled for this report. The prediction should be treated as a hypothesis for investigation, not as evidence of benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 13979R | Parlodel | Tablet 2.5 mg (as mesilate) | Not recorded in the local data |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Interaction screening in the data compiled for this report found 87 recorded interacting drugs. Examples flagged as Major include isometheptene and lorcaserin. Examples flagged as Moderate include morphine, clarithromycin, metoclopramide, promethazine, lansoprazole and ethanol.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score but no supporting trials, literature or mechanistic rationale. The evidence level is L5, so there is no basis to progress it.
To proceed, the following is needed:
- A plausible biological link between dopamine D2 agonism and fucosylation defects, supported by preclinical or mechanistic studies
- Mechanism of action data for bromocriptine
- Product Information warnings and contraindications for safety review
- Any clinical or case-level evidence in this disease
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.